Genotype assays and third-line ART in resource-limited settings: A simulation and cost-effectiveness analysis of a planned clinical trial

AIDS

Volumn 26, Issue 9, 2012, Pages 1083-1093

  Lorenzana, Sarah B ^a   Hughes, Michael D ^c   Grinsztejn, Beatriz ^d   Collier, Ann C ^e   Luz, Paula Mendes ^d   Freedberg, Kenneth A ^a,c   Wood, Robin ^f   Levison, Julie H ^a,b   Mugyenyi, Peter N ^g   Salata, Robert ^h   Wallis, Carole L ⁱ   Weinstein, Milton C ^c   Schooley, Robert T ^j   Walensky, Rochelle P ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d Funda??o Oswaldo Cruz   (Brazil)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^h CASE WESTERN RESERVE UNIVERSITY   (United States)

ⁱ LANCET LABORATORIES   (South Africa)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

A5288; ACTG; antiretroviral therapy; ART; cost effectiveness; genotype; HIV; resource limited setting; third line ART

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COTRIMOXAZOLE; DARUNAVIR PLUS RITONAVIR; ETRAVIRINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL RESISTANCE; ARTICLE; BACTERIAL INFECTION; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GENOTYPING TECHNIQUE; HEALTH CARE DISPARITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MYCOSIS; OUTCOME ASSESSMENT; PATIENT CODING; PRIORITY JOURNAL; SOUTH AFRICA; SURVIVAL RATE; SURVIVAL TIME; VIRUS LOAD;

ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 84861529252     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835221eb     Document Type: Article

References (58)

1. WHO, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010. Available at: http://www.who.int/hiv/pub/2010progressreport/report/en/index.html. Accessed July 18, 2011.
2. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failureamong adults in South Africa. AIDS 2008; 22:1971-1977.
3. Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 46:187-193.
4. Tuboi SH, Harrison LH, Sprinz E, Albernaz RK, Schechter M. Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J Acquir Immune Defic Syndr 2005; 40:324-328.
5. Charles M, Noel F, Leger P, Severe P, Riviere C, Beauharnais CA, et al. Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. Bull World Health Organ 2008; 86:970-977.
6. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Available at: http://www.who.int/hiv/pub/arv/adult2010/en/index.html. Accessed July 18, 2011.
7. Badri M, Lawn SD, Wood R. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis 2008; 8:89.
8. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:480-484.
9. Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, Hampton J, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46:1589-1597.
10. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009; 14:523-531.
11. Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, Deeks SG. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008; 22:2097-2106.
12. Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, et al. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis 2009; 49:1582-1590.
13. Napravnik S, Keys JR, Quinlivan EB, Wohl DA, Mikeal OV, Eron JJ Jr. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. AIDS 2007; 21:825-834.
14. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-line lopinavir/r-containing antiretroviral therapy in South Africa. AIDS Res Treat 2011; 2011:769627.
15. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-1134.
16. Levison JH, Orrell C, Losina E, Lu Z, Freedberg KA, Wood R. Early outcomes and the virologic impact of delayed treatment switching on second-line therapy in an antiretroviral roll-out program in South Africa. Antiviral Ther 2011;16:853-861.
17. El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, Karstaedt A, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS 2010; 24:1679-1687.
18. Murphy RA, Sunpath H, Lu Z, Chelin N, Losina E, Gordon M, et al. Outcomes after virologic failure of first-line ART in South Africa. AIDS 2010; 24:1007-1012.
19. Supply Chain Management System (SCMS). Available at: http://scms.pfscm. org/scms/ecatalog/arvs. Accessed July 18, 2011.
20. Infectious Disease News. HIV resistance testing may be expensive, but is cost effective in the long run. Nov 1, 2007. Available at: http://www. infectiousdiseasenews.com/article/33882.aspx. Accessed July 18, 2011.
21. Wegner SA, Wallace MR, Aronson NE, Tasker SA, Blazes DL, Tamminga C, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis 2004; 38:723-730.
22. Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana MO, et al. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis 2008; 197:1324-1332.
23. Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, et al. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009; 151:157-166.
24. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, et al. Cost-effectiveness of HIV treatment in resource-poor settings: the case of Côte d'Ivoire. N Engl J Med 2006; 355:1141-1153.
25. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Costeffectiveness in health and medicine. New York: Oxford University Press; 1996.
26. Cantor SB, Ganiats TG. Incremental cost-effectiveness analysis: the optimal strategy depends on the strategy set. J Clin Epidemiol 1999; 52:517-522.
27. World Health Organization. CHOosing interventions that are cost-effective (WHO-CHOICE): cost-effectiveness thresholds. Geneva: World Health Organization, 2009. Available at: http://www.who.int/choice/en/. Accessed July 18, 2011.
28. International Monetary Fund (2009). World economic outlook database, October 2010. Available at: http://www.imf.org/external/pubs/ft/weo/2010/02/ weodata/weorept.aspx?pr.x53 &pr. y12&sy2005&ey2015&scsm1&ssd1&sortcoun try&ds. &br1&c199&sNGDPD,NGDPDPC&grp0&a. Accessed July 18, 2011.
29. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4R lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954.
30. Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006; 42:464-469.
31. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19:2109-2116.
32. Cleary S, Boulle A, McIntyre D, et al. Cost-effectiveness of antiretroviral treatment for HIV-positive adults in a South African township. Médecins Sans Frontières and the Health Systems Trust,2004.Available at: http://www.hst.org.za/uploads/files/arv-cost.pdf. Accessed July 18, 2011.
33. Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, Walensky RP, Weinstein MC, et al. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Cô te d'Ivoire: a trial-based analysis. AIDS 2005; 19:1299-1308.
34. Anglaret X, Chene G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999; 353:1463-1468.
35. AIDS Clinical Trials Group. A5288: Management using the latest technologies in resource-limited settings to optimize combination therapy after viral failure. Accessed August 1, 2011.
36. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4R T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181:946-953.
37. Losina E, Yazdanpanah Y, Deuffic-Burban S, Wang B, Wolf LL, Messou E, et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire. Antivir Ther 2007; 12:543-551.
38. Cole SR, Hernan MA, Robins JM, Anastos K, Chmiel J, Detels R, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 2003; 158:687-694.
39. Egger, M. Outcomes of ART in resource-limited and industrialized countries [Plenary Session 21]. 14th CROI Conference on Retroviruses and Opportunistic Infections; Los Angeles, California, USA. February 25-28, 2007.
40. Keiser O, Orrell C, Egger M, Wood R, Brinkhof MW, Furrer H, et al. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 2008; 5:e148.
41. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335-341.
42. Hammond R, Harry TC. Efficacy of antiretroviral therapy in Africa: effect on immunological and virological outcome measures: a meta-analysis. Int J STD AIDS 2008; 19:291-296.
43. Tuboi SH, Brinkhof MW, Egger M, Stone RA, Braitstein P, Nash D, et al. Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 2007; 45:52-59.
44. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
45. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19:685-694.
46. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009; 49:1441-1449.
47. Eron, J. Sustained antiretroviral effect of raltegravir at week 156 in the BENCHMRK studies and exploratory analysis of late outcomes based on early virologic responses [Abstract 515]. 17th CROI Conference on Retroviruses and Opportunistic Infections; San Francisco, California, USA. February 16-19, 2010.
48. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355-365.
49. Clinton Foundation. Clinton Foundation HIV/AIDS Initiative Antiretroviral (ARV) Price List. 2010. Available at: http://www. clintonfoundation.org/files/ chai-arv-priceList-april2010-english. pdf. Accessed July 18, 2011.
50. D'Aquila, Richard T. Overview of HIV-1 resistance assay methods. Available at: http://www.medscape.org/viewarticle/429693-3. Accessed July 18, 2011.
51. Gauteng Department of Health. Gauteng Hospitals Numeric. Gauteng Province, South Africa; 2004.
52. Oanda Corporation. (2009) FXHistory: Historical Currency Exchange Rates. Available at: http://www.oanda.com/currency/historical-rates?date- fmtus&date12/31/09&date101/01/09 &exchZAR&exch2ZAR& exprUSD&expr2USD&margin-fixed0&formatHTML&redirected1. Accessed December 30, 2010.
53. Bendavid E, Grant P, Talbot A, Owens DK, Zolopa A. Costeffectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS 2011; 25:211-220.
54. Ciaranello AL, Lockman S, Freedberg KA, Hughes M, Chu J, Currier J, et al. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS 2011; 25:479-492.
55. Bendavid E, Wood R, Katzenstein DA, Bayoumi AM, Owens DK. Expanding antiretroviral options in resource-limited settings-a cost-effectiveness analysis. J Acquir Immune Defic Syndr 2009; 52:106-113.
56. Clinton Foundation. Press Release: President Clinton, Pfizer, and Mylan announce new agreements to lower prices of medicines for patients with drug-resistant HIV in developing countries. Available at: http://www. clintonfoundation.org/news/news-media/president-bill-clinton-foundation-helps- lower-prices-hiv-medicines.php Accessed July 18, 2011.
57. de Meyer S, Vangeneugden T, van Baelen B, de Paepe E, van Marck H, Picchio G, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008; 24:379-388.
58. Katlama C, Clotet B, Mills A, Trottier B, Molina JM, Grinsztejn B, et al. Efficacy and safety of etravirine at week 96 in treatmentexperienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther 2010; 15:1045-1052.